Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice
A study published in 'Science' suggests that psilocybin, a compound found in magic mushrooms, may prevent chemotherapy-induced neuropathy in mice. Two doses of psilocybin administered before chemotherapy completely blocked the side effect, potentially opening new avenues for using psychedelics beyond mental health treatments. Another study in the 'New England Journal of Medicine' reports that a novel immunotherapy, involving genetically modified T-cells, showed promise in treating autoimmune conditions. Additionally, a small clinical trial indicates that the drug daraxonrasib might be effective against lung cancer, though further research is needed. The article also mentions the Ig Nobel Prize ceremony, highlighting humorous yet scientifically inspired performances.
A new study suggests that psilocybin, the active ingredient in magic mushrooms, might help prevent a serious side effect of chemotherapy known as peripheral neuropathy. Published in the journal Science, the research involved experiments on rats and human tissue samples, focusing on how psilocybin could potentially shield nerve cells from damage caused by chemotherapy treatments. Peripheral neuropathy affects approximately three-quarters of cancer patients undergoing chemotherapy and often leads to persistent numbness, tingling, and severe burning pain. In some cases, the condition can significantly impair mobility and reduce quality of life. A third of affected individuals experience constant, excruciating pain, according to Patrick Dougherty, a co-author of the study and a pain treatment specialist at the University of Texas MD Anderson Cancer Center. Such complications can also interfere with cancer treatment itself, forcing doctors to limit chemotherapy dosages or discontinue therapy altogether. The discovery came unexpectedly during initial studies aimed at understanding how cancer exploits nerve cells for growth. Researchers observed that psilocybin, originally studied for its potential to enhance neuroplasticity, seemed to prevent the onset of neuropathy. Further investigation revealed that psilocybin helps preserve nerve function by maintaining mitochondrial transport within cells. Mitochondria, often described as the powerhouses of cells, play a crucial role in delivering energy to the ends of nerves, areas frequently damaged by chemotherapy. In rodent trials, administering two doses of psilocybin prior to chemotherapy prevented the development of painful hypersensitivity during up to six rounds of treatment. Notably, the intervention did not compromise the effectiveness of chemotherapy in shrinking tumors or affect the animals’ immune responses. These findings suggest that psilocybin could serve as a protective measure against chemotherapy-induced nerve damage without interfering with the primary goal of cancer treatment. Kristy Townsend, a neurobiology professor at The Ohio State University, noted the promising implications of the study. She emphasized that psilocybin’s nerve-protecting properties appear unrelated to its hallucinogenic effects, as a non-hallucinogenic analog produced similar benefits in laboratory settings. However, she acknowledged that further research is necessary to determine the safety and efficacy of psilocybin in humans before it can be considered a standard treatment option. Gregory Jones, a psychiatrist involved in the study, cautioned against self-medication with psilocybin. He pointed out that the drug has an “amplifier” effect, meaning that unregulated use could exacerbate psychological distress among cancer patients. While psilocybin is legal in several U.S. states, experts warn that supervised medical use is essential to ensure patient safety. The MD Anderson Cancer Center plans to initiate clinical trials involving cancer patients later this year, building on the encouraging results from animal models. As interest in psychedelic medicine grows, supported by increased research funding and regulatory reforms, the potential applications of psilocybin continue to expand beyond traditional mental health treatments.
Go to the primary sources (7)
The official sources this coverage is built on. Read them directly to bypass framing.
This research opens up a potential new use for psilocybin, which has already been studied for mental health conditions like depression. The study was conducted in laboratory models and animals, so more research will be needed before it becomes available as a treatment. However, the results are promising and highlight the possibility of using drugs,
A study published in 'Science' suggests that psilocybin, a compound found in magic mushrooms, may prevent chemotherapy-induced neuropathy in mice. Two doses of psilocybin administered before chemotherapy completely blocked the side effect, potentially opening new avenues for using psychedelics beyond mental health treatments. Another study in the 'New England Journal of Medicine' reports that a novel immunotherapy, involving genetically modified T-cells, showed promise in treating autoimmune conditions. Additionally, a small clinical trial indicates that the drug daraxonrasib might be effective against lung cancer, though further research is needed. The article also mentions the Ig Nobel Prize ceremony, highlighting humorous yet scientifically inspired performances.
Bias read (Center): The article presents scientific findings without overt ideological slant. While it discusses potential medical applications of psilocybin, it does not frame these developments through a political lens. The focus remains on scientific progress and medical innovation rather than advocacy for specific政
Why factuality (85): The article accurately reports the study's main findings, including the prevention of neuropathy in mice with two doses of psilocybin. It references the primary source document from Science and aligns with the study's conclusions about psilocybin's neuroprotective effects. However, it omits some det
Why objectivity (75): The tone is generally neutral, but there is a slight promotional undertone suggesting that psilocybin could expand beyond mental health uses. The phrase 'could argue for expanding the use' implies a positive outlook that may not be entirely objective.
A study conducted on mice suggests that psilocybin, a psychoactive compound found in magic mushrooms, may prevent chemotherapy-induced neuropathy. Researchers observed that administering two doses of psilocybin before chemotherapy significantly reduced the development of neuropathy, which affects up to 60% of patients receiving platinum-based cancer treatments. The findings, published in 'Science', indicate that psilocybin might protect nerve fibers by improving mitochondrial function, potentially offering a new preventive strategy for managing this painful side effect. The research highlights a novel application of psilocybin beyond its traditional associations with mental health conditions.
Bias read (Progressive): The article frames psilocybin as a potential medical breakthrough with therapeutic implications, emphasizing its role in preventing a serious side effect of chemotherapy. While the scientific findings are presented objectively, the focus on psilocybin's medicinal benefits aligns with progressive or左
Why factuality (65): The article states that up to 60% of people treated with platinum-based drugs develop neuropathy, which is not directly supported by the primary source. However, it accurately describes the mechanism of action of psilocybin and the study's focus on preventing neuropathy. The reference to the study i
Why objectivity (75): The article presents the findings in a relatively neutral manner, citing the study's results without overtly favoring one perspective. However, it uses phrases like 'unexpected defense' and 'significant efficacy' which may subtly highlight the positive aspects of the discovery without sufficient cou
A U.S. study published in the journal Science explored the potential of psilocybin, the active compound in magic mushrooms, to alleviate the painful side effects of chemotherapy known as peripheral neuropathy. Researchers tested the substance on rats and human tissue, discovering that psilocybin could protect nerve cells and prevent the development of neuropathy by maintaining mitochondrial function and neural activity. The findings suggest that psilocybin might reduce nerve damage caused by chemotherapy, potentially improving patient outcomes and allowing for more aggressive treatments. However, experts caution that further research is needed to confirm safety and efficacy in humans before clinical applications can begin.
Bias read (Center): The article presents scientific findings without overt ideological framing. While psilocybin is a controversial substance due to its psychoactive properties and legal status, the focus remains on medical research and clinical implications rather than political advocacy. The tone is objective, citing
Why factuality (60): The article mentions that peripheral neuropathy affects about three-fourths of all people undergoing chemotherapy, which is inconsistent with the primary source stating that around four in every 10 patients experience persistent severe peripheral nerve pain. It also references a study in Science but
Why objectivity (70): The article uses emotionally charged terms like 'hallucinogenic drug,' 'debilitating complications,' and 'life.' It frames the issue as a 'quality-of-life issue' and emphasizes the potential of psilocybin in a way that may imply optimism without balancing it with the limitations of the study.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.
United Kingdom
